Stereotactic ablative body radiotherapy (SABR)
Topic Status Complete
Stereotactic ablative body radiotherapy (SABR) for oligoprogressive disease.
Summary
Health Technology Wales researchers searched for evidence on the clinical effectiveness and cost effectiveness of Stereotactic ablative body radiotherapy (SABR) to treat oligoprogressive disease. Based on the evidence, HTW’s Assessment Group decided not to progress this topic to full appraisal.
Topic Exploration Report
TER368 07.2022
